Table 1 M3 cohort demographics

Age, years

65 [54–71]

70 [60–79]

62 [49–68]

Male, n (%)

63 (68.5)

23 (74.2)

23 (72)

Weight, kg

93 [80–101]

93 [80–105]

99 [86–105]

Height, cm

173 [165–180]

172 [167–180]

173 [164–180]

BMI, kg/m²

30.9 [27–34]

31.1 [26.1–35]

31.5 [30–34.8]

Comorbidities

 Diabetes

37 (40.2)

15 (48.4)

20 (62.5)

 Hypertension

54 (58.7)

21 (67.7)

17 (53.1)

 Cardiac^a

35 (38)

16 (51.6)

10 (31.2)

 Respiratory^b

16 (17.4)

8 (25.8)

4 (12.5)

 Chronic kidney disease

18 (19.6)

12 (38.7)

2 (6.2)

 Immunosuppression

5 (5.4)

3 (9.7)

1 (3.1)

 SOFA at admission

6 [3–8]

7 [5–8]

7 [4–8]

 SAPS II

36 [28–47]

42 [33–54]

37.5 [30.5–44]

Mechanical ventilation, n (%)

71 (77.2)

28 (90.3)

30 (93.7)

Duration of mechanical ventilation, days

17 [11–26]

13 [6–23]

21 [12–29]

PaO₂/FiO₂ at admission

–

–

97.5 [74.1–131]

Worse PaO₂/FiO₂

–

–

71.1 [62.1–81.1]

Vasopressive support, n (%)

56 (60.9)

24 (77.4)

27 (84.4)

Duration of norepinephrine administration, days

17 [11–26]

4 [1–13]

5 [2–10.5]

Peak creatinine > upper reference value, n (%)

–

–

23 (71.8)

Peak creatinine, mg/dL

–

–

1.7 [1–4.1]

Worse eGFR (MDRD), ml/min/1.73 m²

–

–

40.7 [14.4–65.8]

Renal replacement therapy, n (%)

18 (19.6)

10 (32.3)

5 (15.6)

Extracorporeal membrane oxygenation, n (%)

3 (3.3)

3 (9.7)

0

Peak C-reactive protein, mg/L

–

–

306.4 [253.1–363.2]

ICU LOS, days

16 [7–28]

13 [7–23]

23 [15–39]

Hospital LOS, days

19 [12–28]

14.4 [9–24]

40 [29–52]

Hospital mortality, n (%)

31 (33.7)

31 (100)

–

Destination at hospital discharge

 Home, n (%)

–

–

15 (46.9)

 Rehabilitation facility, n (%)

–

–

17 (53.1)

Rehabilitation center LOS, days

–

–

30 [20–40]